Stock comparison
AxoGen
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AXGN
AxoGen
Market cap
$2.17B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AXGN | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 19F | 65C | GMAB |
| Benjamin Graham | 54D | 64C | GMAB |
| Philip Fisher | 40D | 48D | GMAB |
| Peter Lynch | 27F | 25F | AXGN |
| Joel Greenblatt | 0F | 76B | GMAB |
| Charlie Munger | 26F | 68C | GMAB |
| Terry Smith | 27F | 71C | GMAB |
Side-by-side metrics
| Metric | AXGN | GMAB |
|---|---|---|
| Market cap | $2.17B | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | - | 12.0x |
| ROIC (TTM) | -3.4% | 43.78% |
| Gross margin | 75.01% | 93.88% |
| Net margin | -13.21% | 18.23% |
| Revenue CAGR 5y | 15.32% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AXGN leads on
- Revenue CAGR 5y15.32%vs -18.45%+183%
- P/E (TTM)-vs 6.2x+109%
- EV/EBIT-vs 12.0x+104%
GMAB leads on
- Net margin18.23%vs -13.21%+172%
- ROIC (TTM)43.78%vs -3.4%+108%
- Market cap$16.5Bvs $2.17B+87%
- Gross margin93.88%vs 75.01%+20%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.